Detalhe da pesquisa
1.
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
Blood Cancer J;
14(1): 94, 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38849344
2.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Cancer Med;
13(7): e7071, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38558233
3.
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
Leuk Lymphoma;
65(6): 833-842, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497533
4.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med;
390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
5.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood;
143(7): 592-596, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048557
6.
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
EClinicalMedicine;
60: 102016, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396800
7.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine;
60: 102017, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396807
8.
Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma.
Am J Hematol;
98(9): E230-E232, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317959
9.
COVID-19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation.
Hematol Oncol;
41(3): 555-558, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36786526
10.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica;
108(3): 833-842, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200419
11.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol;
24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528035
12.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol;
40(27): 3120-3131, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35666982
13.
RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment.
Cancers (Basel);
14(9)2022 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35565401
14.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol;
40(4): 704-715, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608183
15.
The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.
Ann Hematol;
101(6): 1227-1237, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380239
16.
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Blood Cancer J;
11(12): 197, 2021 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34876566
17.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol;
22(12): 1705-1720, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774221
18.
Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
Cancer Med;
10(17): 5859-5865, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34263564
19.
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.
Blood;
138(18): 1705-1720, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34077955
20.
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients.
Clin Cancer Res;
27(13): 3695-3703, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33926915